Archive for December, 2008
Artificial bone marrow that can continuously make red and white blood cells has been created in a University of Michigan lab. This development could lead to simpler pharmaceutical drug testing, closer study of immune system defects and a continuous supply of blood for transfusions.
More: continued here
A new report demonstrates how a sensitive imaging technique gives scientists the upper hand in seeking out bacteria in chronic infections. Listeria monocytogenes is a type of pathogenic bacteria that can cause severe illness and death. Listeria outbreaks recently claimed twenty lives in Canada. Additionally, Listeria infection is the third most common cause of bacterial meningitis in newborns, and can cause abortion and stillbirth.
More: continued here
Head banging increases the risk of head and neck injury, but the effects may be lessened with reduced head and neck motion, head banging to lower tempo songs or to every second beat, and using protective equipment such as neck braces, finds a study in the Christmas issue published on bmj.com.
More: continued here
Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) announced today that a Phase III clinical study of Rituxan® (rituximab) in patients with early rheumatoid arthritis (RA) who have not previously been treated with methotrexate (MTX) met its primary endpoint. In this study, known as IMAGE, patients received two infusions of either 500 mg or 1000 mg of Rituxan or placebo for up to two treatment courses in combination with a stable dose of MTX.
More: continued here
Exactech, Inc. (Nasdaq:EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, said that surgeons are experiencing excellent early results with its new Optetrak® CR Slope™ knee system. Introduced in Q4 2008, the patent-pending CR Slope design builds on the company’s flagship Optetrak knee system.
More: continued here
CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc. (Emeryville, CA) announced positive results from a Phase IIa osteoarthritis (OA) study of the efficacy and safety of a next-generation NSAID, CG100649. The CG100649 treatment group met the primary efficacy endpoint by demonstrating a clinically and statistically significant change in the WOMAC(TM) OA score from baseline to Day 21 (p=0.010) compared to placebo.
More: continued here
The AMA has called for better coordination across the medical profession and other health providers in alerting patients to the early signs of osteoporosis. “The release of the Australian Institute of Health and Welfare report on Arthritis and Osteoporosis in Australia (2008) is a reminder that we need to ensure we have sound arrangements for the long-term management of osteoporosis,” AMA President, Dr Rosanna Capolingua, said.
More: continued here
Genzyme Corporation (Nasdaq: GENZ) has announced that the U.S. Food and Drug Administration has granted marketing approval for Mozobil™ (plerixafor injection), a drug intended to be used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).
More: continued here
More and more composite tissue grafts are worldwide performed. This kind of graft implies to take a sample of all necessary tissues and vascular and nervous elements for the reconstruction of a given area. This includes elbow, arm, hand and face transplantations and requires surgical skill and a multidisciplinary approach.
More: continued here
New research claims long-term use of Thiazolidinediones, a class of drugs used to manage Type 2 diabetes, could potentially double some women’s risk of breaking a bone. The research by British and American scientists analysed the findings of ten studies involving almost 14,000 people with Type 2 diabetes. The researchers, from the University of East Anglia and Wake Forest University in North Carolina, compared the bone health of those on the drugs with others who were not.
More: continued here





